After supplementation with dietary lycopene (2.2 and 6.6 mg/kg BW/day, respectively) for 26 weeks, the researchers found that lycopene can mitigate NKK-induced MASH in a dose-dependent manner by downregulating CYP2E1 and inflammatory NF-κB [198]. Here, CYP2E1 is linked to metabolic dysfunction-associated steatohepatitis.